Dentons Hong Kong has advised Goldman Sachs and Haitong International Capital on the initial public offering of Broncus Holding Corporation on the Hong Kong Stock Exchange under Chapter 18A of the Listing Rules. The offering is aimed at raising net proceeds of approximately US$191 million. Broncus is a leading interventional pulmonology medical device player in China and globally and has developed an integrated interventional pulmonology platform encompassing navigation, diagnosis and treatment, which addresses the pain points of the existing diagnosis and treatment paradigms.
The Dentons Hong Kong team is led by capital markets partner Gordon Ng and associate Ningxin Sun.
Redefining possibilities. Together, everywhere. For more information visit dentons.com
heading